Share This Article:

Molecular Targeted Therapy of Hepatocellular Carcinoma

Abstract Full-Text HTML XML Download Download as PDF (Size:440KB) PP. 426-439
DOI: 10.4236/jct.2013.42A052    5,534 Downloads   8,633 Views   Citations


Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related mortality worldwide. Despite decades of efforts by many investigators, systemic chemotherapy or hormonal therapy has notoriously failed to show an improvement in survival. With a median survival of 8 months, and 1- and 3-year survival rates of 20% and 5%, respectively, the effective treatment of HCC remains far from satisfactory. Better understanding of the pathogenesis of this disease, identification of molecular targets for therapeutic intervention and availability of promising molecularly targeted therapies may change this dismal picture. In this review we will focus on what is currently known about the molecular pathogenesis of HCC, and explore the currently available and future molecular based therapies targeting these pathways. Future research in this area will maximize clinical benefit while minimizing the toxicity and cost through utilization of novel targeted agents.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

K. Terry and M. Copur, "Molecular Targeted Therapy of Hepatocellular Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 2A, 2013, pp. 426-439. doi: 10.4236/jct.2013.42A052.


[1] F. X. Bosch, J. Ribes, R. Cleries and M. Diaz, “Epidemiology of Hepatocellular Carcinoma,” Clinical Liver Disease, Vol. 9, No. 2, 2005, pp. 191-211. doi:10.1016/j.cld.2004.12.009
[2] P. Pisani, F. Bray and D. M. Parkin, “Estimates of the World-Wide Prevalence of Cancer for 25 Sites in the Adult Population,” International Journal of Cancer, Vol. 97, No. 1, 2002, pp. 72-81. doi:10.1002/ijc.1571
[3] H. B. El-Serag, “Epidemiology of Hepatocellular Carcinoma in USA,” Hepatology Research, Vol. 37, Suppl. 2, 2007, pp. S88-S94. doi:10.1111/j.1872-034X.2007.00168.x
[4] Z. F. Yang and R. T. Poon, “Vascular Changes in Hepatocellular Carcinoma,” The Anatomical Record, Vol. 291, No. 6, 2008, pp. 721-734. doi:10.1002/ar.20668
[5] W. S. Moon, K. H. Rhyu, M. J. Kang, D. G. Lee, H. C. Yu, J. H. Yeum, et al., “Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma?” Modern Pathology, Vol. 16, No. 6, 2003, pp. 552-557. doi:10.1097/01.MP.0000071841.17900.69
[6] H. Yoshiji, S. Kuriyama, J. Yoshii, M. Yamazaki, M. Kikukawa, H. Tsujinoue, et al., “Vascular Endothelial Growth Factor Tightly Regulates in Vivo Development of Murine Hepatocellular Carcinoma Cells,” Hepatology, Vol. 28, No. 6, 1998, pp. 1489-1496. doi:10.1002/hep.510280607
[7] Y. Chao, C. P. Li, G. Y. Chau, et al., “Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients with Resectable Hepatocellular Carcinoma after Surgery,” Annals of Surgical Oncology, Vol. 10, No. 4, 2003, pp. 355-362. doi:10.1245/ASO.2003.10.002
[8] K. S. Jeng, I. S. Sheen, Y. C. Wang, et al., “Prognostic Significance of Preoperative Circulating Vascular Endothelial Growth Factor Messenger RNA Expression in Resectable Hepatocellular Carcinoma: A Prospective Study,” World Journal of Gastroenterology, Vol. 10, No. 5, 2004, pp. 643-648.
[9] R. T. Poon, J. W. Ho, C. S. Tong, et al., “Prognostic Significance of Serum Vascular Endothelial Growth Factor and Endostatin in Patients with Hepatocellular Carcinoma,” British Journal of Surgery, Vol. 91, No. 10, 2004, pp. 1354-1360. doi:10.1002/bjs.4594
[10] J. M. Llovet, S. Ricci, V. Mazzaferro, et al., “Sorafenib in Advanced Hepatocellular Carcinoma,” The New England Journal of Medicine, Vol. 359, 2008, pp. 378-390. doi:10.1056/NEJMoa0708857
[11] A. B. Siegel, E. I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, J. J. Knox, et al., “Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 26, No. 18, 2008, pp. 2992-2998. doi:10.1200/JCO.2007.15.9947
[12] A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, A. Muzikansky, K. Horgan, et al., “Phase II Study of Gemcitabine and Oxaliplatin in Combination with Bevacizumab in Patients with Advanced Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 24, No. 12, 2006, pp. 1898-1903. doi:10.1200/JCO.2005.04.9130
[13] J. M. Wood, “Inhibition of vascular Endothelial Growth Factor (VEGF) as a Novel Approach for Cancer Therapy,” Medicina (B Aires), 60, Suppl. 2, 2000, pp. 41-47.
[14] J. Drevs, R. Muller-Driver, C. Wittig, et al., “PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging,” Cancer Research, Vol. 62, No. 14, 2002, pp. 4015-4022.
[15] I. Koch, A. Baron, S. Roberts, et al., “Influence of Hepatic Dysfunction on Safety, Tolerability, and Pharmacokinetics (PK) of PTK787/ZK 222584 in Patients (pts) with Unresectable Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 23, Suppl. 4134, 2007.
[16] S. R. Wedge, J. Kendrew, L. F. Hennequin, P. J. Valentine, S. T. Barry, S. R. Brave, N. R. Smith, N. H. James, M. Dukes, J. O. Curwen, et al., “AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer,” Cancer Research, Vol. 65, No. 10, 2005, pp. 4389-4400. doi:10.1158/0008-5472.CAN-04-4409
[17] J. Drevs, P. Siegert, M. Medinger, K. Mross, R. Strecker, U. Zirrgiebel, J. Harder, H. Blum, J. Robertson, J. M. Jurgensmeier, et al., “Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients with Advanced Solid Tumors,” Journal of Clinical Oncology, Vol. 25, No. 21, 2007, pp. 3045-3054. doi:10.1200/JCO.2006.07.2066
[18] S. R. Alberts, T. R. Fitch, G. P. Kim, B. W. Morlan, S. R. Dakhil, H. M. Gross and S. Nair, “Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial,” American Journal of Clinical Oncology, Vol. 35, No. 4, 2012, pp. 329-333. doi:10.1097/COC.0b013e3182118cdf
[19] J. L. Raoul, R. S. Finn, Y. K. Kang, et al., “An Open-Label Phase II Study of First- and Second-Line Treatment with Brivanib in Patients with Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 27, Suppl. 4577, 2009.
[20] D. B. Mendel, A. D. Laird, X. Xin, et al., “In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Receptors: Determination of a pharmacokinetic/Pharmacodynamic Relationship,” Clinical Cancer Research, Vol. 9, No. 1, 2003, pp. 327- 337.
[21] A. X. Zhu, D. V. Sahani, D. G. Duda, et al., “Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study,” Journal of Clinical Oncology, Vol. 27, No. 18, 2009, pp. 3027-3035. doi:10.1200/JCO.2008.20.9908
[22] S. Faivre, E. Raymond, E. Boucher, et al., “Safety and Efficacy of Sunitinib in Patients with Advanced Hepatocellular Carcinoma: An Open-Label, Multicentre, Phase II Study,” The Lancet Oncology, Vol. 10, No. 8, 2009, pp. 794-800. doi:10.1016/S1470-2045(09)70171-8
[23] T. Yau, P. J. Chen, P. Chan, et al., “Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics,” Clinical Cancer Research, Vol. 17, No. 21, 2011, pp. 6914-6923. doi:10.1158/1078-0432.CCR-11-0793
[24] C. C. Yau, P. J. Chen, C. M. Curtis, et al., “A Phase I Study of Pazopanib in Patients with Advanced Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 27, Suppl. 3561, 2009 (Abstr 3561).
[25] H. Toh, P. Chen, I. Carr, et al., “Linifanib Phase II Trial in Patients with Advanced Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 28, Suppl. 15s, 2010 (Abstr 4038).
[26] C. R. Carlin, D. Simon, J. Mattison and B. B. Knowles, “Expression and Biosynthetic Variation of the Epidermal Growth Factor Receptor in Human Hepatocellular Carcinoma-Derived Cell Lines,” Molecular and Cellular Biology, Vol. 8, No. 1, 1998, pp. 25-34.
[27] K. Harada, G. Shiota and H. Kawasaki, “Transforming Growth Factor Alpha and Epidermal Growth Factor Receptor in Chronic Liver Disease and Hepatocellular Carcinoma,” Liver, Vol. 19, No. 4, 1999, pp. 318-325. doi:10.1111/j.1478-3231.1999.tb00056.x
[28] Y. Ito, T. Takeda, S. Higashiyama, et al., “Expression of Heparin Binding Epidermal Growth Factor-Like Growth Factor in Hepatocellular Carcinoma: An Immunohistochemical Study,” Oncology Reports, Vol. 8, No. 1, 2001, pp. 903-907.
[29] S. Kira, T. Nakanishi, S. Suemori, et al., “Expression of Transforming Growth Factor Alpha and Epidermal Growth Factor Receptor in Human Hepatocellular Carcinoma,” Liver, Vol. 17, No. 4, 1997, pp. 177-182. doi:10.1111/j.1600-0676.1997.tb00803.x
[30] A. Kiss, N. J. Wang, J. P. Xie and S. S. Thorgeirsson, “Analysis of Transforming Growth Factor (TGF)-Alpha/ Epidermal Growth Factor Receptor, Hepatocyte Growth Factor/c-Met, TGF-Beta Receptor Type II, and p53 Expression in Human Hepatocellular Carcinomas,” Clinical Cancer Research, Vol. 3, No. 7, 1997, pp. 1059-1066.
[31] V. Gruenwald, L. Wilkens, M. Gebel, et al., “A Phase II Open-Label Study of Cetuximab in Unresectable Hepatocellular Carcinoma: Final Results,” Journal of Clinical Oncology, Vol. 25, No. 18, 2007.
[32] A. X. Zhu, K. Stuart, L. S. Blaszkowsky, et al., “Phase 2 Study of Cetuximab in Patients with Advanced Hepatocellular Carcinoma,” Cancer, Vol. 110, No. 3, 2007, pp. 581-589. doi:10.1002/cncr.22829
[33] B. H. O’Neil, S. A. Bernard, R. M. Goldberg, et al., “Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 26, Suppl. 4604, 2008 (Abstr 4604).
[34] S. Louafi, V. Boige, M. Ducreux, et al., “Gemcitabine plus Oxaliplatin (GEMOX) in Patients with Advanced Hepatocellular Carcinoma (HCC): Results of a Phase II Study,” Cancer, Vol. 109, 2007, pp. 1384-1390. doi:10.1002/cncr.22532
[35] M. B. Thomas, R. Chadha, K. Glover, et al., “Phase 2 Study of Erlotinib in Patients with Unresectable Hepatocellular Carcinoma,” Cancer, Vol. 110, No. 5, 2007, pp. 1059-1067. doi:10.1002/cncr.22886
[36] E. G. Chiorean, R. Ramasubbaiah, M. Yu, et al., “Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101,” Oncologist, Vol. 17, No. 1, 2011, p. 13.
[37] M. B. Thomas, J. S. Morris and R. Chadha, “Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 27, No. 6, 2009, pp. 843-850.
[38] P. J. O’Dwyer, B. J. Giantonio, D. E. Levy, et al., “Gefitinib in Advanced Unresectable Hepatocellular Carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203,” Journal of Clinical Oncology, Vol. 24, No. 18S, 2006, p. 4143.
[39] T. Bekaii-Saab, J. Markowitz, N. Prescott, et al., “A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas,” Clinical Cancer Research, Vol. 15, No. 18, 2009, pp. 5895-5901.
[40] J. Bruix and J. M. Llovet, “Major Achievements in Hepatocellular Carcinoma,” Lancet, Vol. 373, No. 9664, 2009, pp. 614-616. doi:10.1016/S0140-6736(09)60381-0
[41] E. E. Calle, C. Rodriguez, K. Walker-Thurmond and M. J. Thun, “Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of US Adults,” The New England Journal of Medicine, Vol. 348, 2003, pp. 1625-1638. doi:10.1056/NEJMoa021423
[42] J. G. Scharf and T. Braulke, “The Role of the IGF Axis in Hepatocarcinogenesis,” Hormone and Metabolic Research, Vol. 35, No. 11-12, 2003, pp. 685-693. doi:10.1055/s-2004-814151
[43] T. Nussbaum, J. Samarin, V. Ehemann, M. Bissinger, E. Ryschich, A. Khamidjanov, X. Yu, N. Gretz, P. Schirmacher and K. Breuhahn, “Autocrine Insulin-Like Growth Factor-II Stimulation of Tumor Cell Migration Is a Progression Step in human Hepatocarcinogenesis,” Hepatology, Vol. 48, No. 1, 2008, pp. 146-156. doi:10.1002/hep.22297
[44] K. Breuhahn and P. Schirmacher, “Reactivation of the Insulin-Like Growth Factor-II Signaling Pathway in Human Hepatocellular Carcinoma,” World Journal of Gastroenterology, Vol. 14, No. 11, 2008, pp. 1690-1698. doi:10.3748/wjg.14.1690
[45] E. Cariani, D. Seurin, C. Lasserre, D. Franco, M. Binoux and C. Brechot, “Expression of Insulin-Like Growth Factor II (IGF-II) in Human Primary Liver Cancer: mRNA and Protein Analysis,” Journal of Hepatology, Vol. 11, No. 2, 1990, pp. 226-231. doi:10.1016/0168-8278(90)90118-B
[46] K. Breuhahn, S. Vreden, R. Haddad, S. Beckebaum, D. Stippel, P. Flemming, T. Nussbaum, W. H. Caselmann, B. B. Haab and P. Schirmacher, “Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression,” Cancer Research, Vol. 64, No. 17, 2004, pp. 6058-6064. doi:10.1158/0008-5472.CAN-04-0292
[47] F. M. Barlaskar and G. D. Hammer, “The Molecular Genetics of Adrenocortical Carcinoma,” Reviews in Endocrine & Metabolic Disorders, Vol. 8, No. 4, 2007, pp. 343-348. doi:10.1007/s11154-007-9057-x
[48] Z. Wang, Y. B. Ruan, Y. Guan and S. H. Liu, “Expression of IGF-II in Early Experimental Hepatocellular Carcinomas and Its Significance in Early Diagnosis,” World Journal of Gastroenterology, Vol. 9, No. 2, 2003, pp. 267- 270.
[49] P. Haluska, J. M. Carboni, D. A. Loegering, et al., “In Vitro and in Vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417,” Cancer Research, Vol. 66, No. 1, 2003, pp. 362-371. doi:10.1158/0008-5472.CAN-05-1107
[50] V. Tovar, C. Alsinet, A. Villanueva, et al., “IGF Activation in a Molecular Subclass of Hepatocellular Carcinoma and Pre-Clinical Efficacy of IGF-1R Blockage,” Journal of Hepatology, Vol. 52, No. 4, 2010, pp. 550-559. doi:10.1016/j.jhep.2010.01.015
[51] C. S. Higano, E. Y. Yu, S. H. Whiting, et al., “A Phase I, First in Man Study of Weekly IMC-A12, a Fully Human Insulin Like Growth Factor-I Receptor IgG1 Monoclonal Antibody, in Patients with Advanced Solid Tumors,” Journal of Clinical Oncology, Vol. 25, No. 18S, 2007, p. 3505.
[52] G. K. Abou-Alfa, B. Gansukh, J. F. Chou, et al., “Phase II Study of Cixutumumab (IMC-A12, NSC742460; C) in Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 29, 2011 (Abstract 4043).
[53] S. J. Faivre, L. Fartoux, M. Bouattour, F. et al., “A Phase I Study of AVE1642, a Human Monoclonal Antibody-Blocking Insulin-Like Growth Factor-1 Receptor (IGF-1R), Given as a Single Agent and in Combination with Sorafenib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma (HCC),” Journal of Clinical Oncology, Vol. 29, Suppl. 4, 2011 (Abstr 270).
[54] Biogen-Idec Inc., “Investigator’ Brochure of BIIB-022,” 2010.
[55] J. A. McCubrey, L. S. Steelman, S. L. Abrams, W. H. Chappell, S. Russo, R. Ove, M. Milella, A. Tafuri, P. Lunghi, A. Bonati, F. Stivala, F. Nicoletti, M. Libra, A. M. Martelli, G. Montalto and M. Cervello, “Emerging MEK Inhibitors,” Expert Opinion on Emerging Drugs, Vol. 15, No. 2, 2010, 203-223, pp. 633-648.
[56] J. Xing, D. D. Ginty and M. E. Greenberg, “Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase,” Science, Vol. 273, No. 5277, 1996, pp. 959-963. doi:10.1126/science.273.5277.959
[57] D. F. Calvisi, S. Ladu, A. Gordon, M. Farina, E. A. Conner, J. S. Lee, V. M. Factor and S. S. Thorgeirsson, “Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC,” Gastroenerology, Vol. 130, No. 4, 2006, pp. 1117-1128. doi:10.1053/j.gastro.2006.01.006
[58] H. Huynh, P. K. Chow, L. L. Ooi and K. C. Soo, “A Possible Role for Insulin-Like Growth Factor-Binding Protein-3 autocrine/Paracrine Loops in Controlling Hepatocellular Carcinoma Cell Proliferation,” Cell Growth Differ, Vol. 13, No. 3, 2002, pp. 115-122.
[59] R. Kannangai, F. Sahin and M. S. Torbenson, “EGFR Is Phosphorylated at Ty845 in Hepatocellular Carcinoma,” Modern Pathology, Vol. 19, No. 11, 2006, pp. 1456-1461.
[60] J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, A. C. de Oliveira, A. Santoro, J. L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T. F. Greten, P. R. Galle, et al., “SHARP Investigators Study Group. Sorafenib in Advanced Hepatocellular Carcinoma,” The New England Journal of Medicine, Vol. 359, 2008, pp. 378-390. doi:10.1056/NEJMoa0708857
[61] B. R. Davies, A. Logie, J. S. McKay, et al., “AZD6244 (ARRY-142886), a Potent Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase 1/2 Kinases: Mechanism of Action in Vivo, Pharmacokinetic/Pharmacodynamic Relationship, and Potential for Combination in Preclinical Models,” Molecular Cancer Therapeutics, Vol. 6, No. 8, 2007, pp. 2209-2219. doi:10.1158/1535-7163.MCT-07-0231
[62] A. A. Adjei, R. B. Cohen, W. Franklin, et al., “Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients with Advanced Cancers,” Journal of Clinical Oncology, Vol. 26, No. 13, 2008, pp. 2139-2146. doi:10.1200/JCO.2007.14.4956
[63] Bolondi, et al., “Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Sec- and -Line Therapy in Patients with Hepatocellular Carcinoma September 26 at the 2011 European Multidisciplinary Cancer Congress,” Abstract 6576, 2011.
[64] D. M. Sabatini, “mTOR and Cancer: Insights into a Complex Relationship,” Nature Reviews Cancer, Vol. 6, No. 9, 2006, pp. 729-734. doi:10.1038/nrc1974
[65] K. J. Schmitz, J. Wohlschlaeger, H. Lang, G. C. Sotiropoulos, M. Malago, K. Steveling, H. Reis, et al., “Activation of the ERK and AKT Signalling Pathway Predicts Poor Prognosis in Hepatocellular Carcinoma and ERK Activation in Cancer Tissue Is Associated with Hepatitis C Virus Infection,” Journal of Hepatology, Vol. 48, No. 1, 2008, pp. 83-90. doi:10.1016/j.jhep.2007.08.018
[66] A Villanueva, DY Chiang, P Newell, et al., “Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma,” Gastroenterology, Vol. 135, No. 6, 2008, pp. 1972-1983, 1983.e1-e11.
[67] L. D. Zhou, Y. Huang, J. D. Li and Z. M. Wang, “The mTOR Pathway Is Associated with the Poor Prognosis of Human Hepatocellular Carcinoma,” Medical Oncology, Vol. 27, No. 2, 2010, pp. 255-261. doi:10.1007/s12032-009-9201-4
[68] T. H. Hu, C. C. Huang, P. R. Lin, H. W. Chang, L. P. Ger, Y. W. Lin, C. S. Changchien, C. M. Lee and M. H. Tai, “Expression and Prognostic Role of Tumor Suppressor gene PTEN/MMAC1 Mutations in Hepatocellular Carcinoma,” Cancer Investigation, Vol. 18, No. 2, 2000, pp. 123-129. doi:10.3109/07357900009038243
[69] K. F. Chen, H. L. Chen, W. T. Tai, W. C. Feng, C. H. Hsu, P. J. Chen and A. L. Cheng, “Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells,” Journal of Pharmacology and Experimental Therapeutics, Vol. 337, No. 1, 2011, pp. 155-161. doi:10.1124/jpet.110.175786
[70] H. Asahina, H. Nokihara, N. Yamamoto, Y. Yamada, Y. Tamura, K. Honda, Y. Seki, Y. Tanabe, H. Shimada, X. Shi and T. Tamura, “Safety and Tolerability of AZD8055 in Japanese Patients with Advanced Solid Tumors; a Dose-Finding Phase I Study,” Investigational New Drugs, 2012.
[71] A. X. Zhu, T. A. Abrams, R. Miksad, L. S. Blaszkowsky, J. A. Meyerhardt, H. Zheng, A. Muzikansky, J. W. Clark, E. L. Kwak, D. Schrag, K. R. Jors, C. S. Fuchs, A. J. Iafrate, D. R. Borger and D. P. Ryan, “Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma,” Cancer, Vol. 117, No. 22, 2011, pp. 5094-5102. doi:10.1002/cncr.26165
[72] T. Decaens, A. Luciani, E. Itti, A. Hulin, F. Roudot-Thoraval, A. Laurent, E. S. Zafrani, A. Mallat and C. Duvoux, “Phase II Study of Sirolimus in Treatment- Naive Patients with advanced Hepatocellular Carcinoma,” Digestive and Liver Disease, Vol. 44, No. 7, 2012, pp. 610-616. doi:10.1016/j.dld.2012.02.005
[73] M. Rizell, M. Andersson, C. Cahlin, L. Hafstrom, M. Olausson and P. Lindnér, “Effects of the mTOR Inhibitor Sirolimus in Patients with Hepatocellular and Cholangiocellular Cancer,” International Journal of Clinical Oncology, Vol. 13, No. 1, 2008, pp. 66-70. doi:10.1007/s10147-007-0733-3
[74] Q. Zhou, V. W. Lui, C. P. Lau, S. H. Cheng, M. H. Ng, Y. Cai, S. L. Chan and W. Yeo, “Sustained Antitumor Activity by Co-Targeting mTOR and the Microtubule with Temsirolimus/Vinblastine Combination in Hepatocellular Carcinoma,” Biochemical Pharmacology, Vol. 83, No. 9, 2012, pp. 1146-1158. doi:10.1016/j.bcp.2012.01.013
[75] C. Herencia, J. M. Martínez-Moreno, C. Herrera, F. Corrales, R. Santiago-Mora, I. Espejo, M. Barco, Y. Almadén, M. de la Mata, A. Rodríguez-Ariza and J. R. Munoz-Castaneda, “Nuclear Translocation of β-Catenin during Mesenchymal Stem Cells Differentiation into Hepatocytes Is Associated with a Tumoral Phenotype,” PLoS One, Vol. 7, No. 4, 2012, Article ID: e34656. doi:10.1371/journal.pone.0034656
[76] H. Fujii, K. Moriya, Y. Shintani, T. Tsutsumi, T. Takayama, M. Makuuchi, S. Kimura and K. Koike, “Frequent Beta-Catenin Abberation in Human Hepatocellular Carcinomas,” Oncogene, Vol. 20, No. 1, 2007, pp. 39-51.
[77] Y. Zhang, W. Wei, N. Cheng, K. Wang, B. Li, X. Jiang and S. Sun, “Hepatitis C Virus-Induced Up-Regulation of Microrna-155 Promotes Hepatocarcinogenesis by Activating Wnt Signaling,” Hepatology, Vol. 56, No. 5, 2012, pp. 1631-1640. doi:10.1002/hep.25849
[78] R. Srisuttee, S. S. Koh, S. J. Kim, W. Malilas, W. Boonying, I. R. Cho, B. H. Jhun, M. Ito, Y. Horio, E. Seto, S. Oh and Y. H. Chung, “Hepatitis B Virus X (HBX) Protein Upregulates β-Catenin in a Human Hepatic Cell Line by Sequestering SIRT1 Deacetylase,” Oncology Reports, Vol. 28, No. 1, 2012, pp. 276-282.
[79] W. Wei, M. Chua, S. Grepper and S. So, “Small Molecule Antagonists of Tcf4/b-Catenin Complex Inhibit the Growth of HCC cells in Vitro and in Vivo,” International Journal of Cancer, Vol. 126, No. 10, 2010, pp. 2426-2436.
[80] M. Pasca di Magliano and M. Hebrok, “Hedgehog Signalling in Cancer Formation and Maintenance,” Nature Reviews Cancer, Vol. 3, No. 12, 2003, pp. 903-911. doi:10.1038/nrc1229
[81] M. A. Patil, J. Zhang, C. Ho, S. T. Fan and X. Chen, “Hedgehog Signaling in Human Hepatocellular Carcinoma,” Cancer Biology& Therapy, Vol. 5, No. 1, 2006, pp. 111-117.
[82] J. K. Sicklick, “Dysregulation of the Hedgehog Pathway in human Hepatocarcinogenesis,” Carcinogenesis, Vol. 27, No. 4, 2006, pp. 748-757. doi:10.1093/carcin/bgi292
[83] J. L. Mullor, N. Dahmane, T. Sun and A. A. Ruizi, “Wnt Signals Are Targets and Mediators of Gli Function,” Current Biology, Vol. 11, No. 10, 2001, pp. 769-773. doi:10.1016/S0960-9822(01)00229-9
[84] C. Niemann, A. B. Unden, S. Lyle, Ch. C. Zouboulis, R. Toftgard and F. M. Watt, “Indian Hedgehog and β-Catenin Signaling: Role in the Sebaceous Lineage of Normal and Neoplastic Mammalian Epidermis,” Proceedings of the National Academy of Sciences of the United States, Vol. 100, Suppl. 1, 2003, pp. 11873-11880. doi:10.1073/pnas.1834202100
[85] Y. Xu, V. Chenna, C. Hu, H. X. Sun, M. Khan, H. Bai, X. R. Yang, Q. F. Zhu, Y. F. Sun, A. Maitra, J. Fan and R. A. Anders, “Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma,” Clinical Cancer Research, Vol. 18, No. 5, 2012, pp. 1291-1302. doi:10.1158/1078-0432.CCR-11-0950
[86] G. Giannelli, A. Mazzocca, E. Fransvea, M. Lahn and S. Antonaci, “Inhibiting TGF-β Signaling in Hepatocellular Carcinoma,” Biochimica et Biophysica Acta, Vol. 1815, No. 2, 2011, pp. 214-223.
[87] T. Ueki, J. Fujimoto, T. Suzuki, H. Yamamoto and E. Okamoto, “Expression of Hepatocyte Growth Factor and Its Receptor, the c-Met Proto-Oncogene, in Hepatocellular Carcinoma,” Hepatology, Vol. 25, No. 3, 1997, pp. 619-623. doi:10.1002/hep.510250321
[88] P. Kaposi-Novak, J. S. Lee, L. Gomez-Quiroz, C. Coulouarn, V. M. Factor and S. S. Thorgeirsson, “Met-Regulated Expression Signature Defines a Subset of Human Hepatocellular Carcinomas with Poor Prognosis And Aggressive Phenotype,” Journal of Clinical Investigation, Vol. 116, No. 6, 2006, pp. 1582-1595. doi:10.1172/JCI27236
[89] J. Avruch, D. Zhou, J. Fitamant and N. Bardeesy, “Mst1/2 Signalling to Yap: Gatekeeper for Liver Size and Tumour Development,” British Journal of Cancer, Vol. 104, No. 1, 2011, pp. 24-32. doi:10.1038/sj.bjc.6606011
[90] L. Gramantieri, C. Giovannini, A. Lanzi, P. Chieco, M. Ravaioli, A. Venturi, G. L. Grazi and L. Bolondi, “Aberrant Notch3 and Notch4 Expression in Human Hepatocellular Carcinoma,” Liver International, Vol. 27, No. 7, 2007, pp. 997-1007. doi:10.1111/j.1478-3231.2007.01544.x
[91] J. Gao, Z. Song, Y. Chen, L. Xia, J. Wang, R. Fan, R. Du, F. Zhang, L. Hong, J. Song, X. Zou, H. Xu, G. Zheng, J. Liu and D. Fan, “Deregulated Expression of Notch Receptors in Human Hepatocellular Carcinoma,” Digestive and Liver Disease, Vol. 40, No. 2, 2008, pp. 114-121. doi:10.1016/j.dld.2007.08.001
[92] I. Borbath, C. Porta, L. Rimassa, et al., “Randomized Controlled Phase 2 Study (RCT) with Tivantinib in Pre-Treated Hepatocellular Carcinoma (HCC): Efficacy, Safety, and MET-Analysis,” 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012), Abstract 114, Boston, 9-13 November 2012.
[93] H. Safran, K. Charpentier, G. Dubel, et al., “Lenalidomide for Second-Line Treatment of Advanced Hepatocellular Cancer (HCC): A Brown University Oncology Group Phase II Study,” Journal of Clinical Oncology, Vol. 30, 2012 (Abstr 4098).

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.